

# Amphastar Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2018

May 10, 2018

RANCHO CUCAMONGA, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President, and Bill Peters, CFO, will be presenting at the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 15, 2018 at 1:00 p.m. Pacific Time in Las Vegas, NV.

This presentation will be made available with a live webcast and may be accessed by visiting Amphastar's Pharmaceuticals website at <http://ir.amphastar.com> . This webcast will be available for 90 days following the presentation.

## **About Amphastar:**

Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information is available at the Company's website at [www.amphastar.com](http://www.amphastar.com).

The Amphastar Pharmaceuticals' logo and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but not limited to Primatene<sup>®</sup>, Amphadase<sup>®</sup> and Cortrosyn<sup>®</sup>, are the property of Amphastar Pharmaceuticals, Inc.

## **Forward-Looking Statement:**

All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to the Company's expectations regarding future financial performance, backlog, sales and marketing of its products, market size and growth, the timing of FDA filings or approvals, acquisitions and other matters related to its pipeline of product candidates, the timing for completion of construction at the Company's IMS facility, its share buyback program and other future events. These statements are not historical facts but rather are based on Amphastar's historical performance and its current expectations, estimates, and projections regarding Amphastar's business, operations and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking

statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission.

Contact:

William J. Peters  
Chief Financial Officer  
(909) 476-3416

Source: Amphastar Pharmaceuticals, Inc.